SCHEMBL30500773

SCHEMBL30500773

Cc1cnn2ncc(CNC(=O)c3ccc(OC(F)(F)F)c(F)c3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 3/20 0.42
▸ ROCK1 Q13464 1/20 0.42
▸ SCN3A Q9NY46 5/20 0.42
▸ EPHX2 P34913 5/20 0.40
▸ PPARG P37231 3/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ SCN1A P35498 2/20 0.38
▸ SCN5A Q14524 2/20 0.38
▸ SCN9A Q15858 2/20 0.38
▸ SCN2A Q99250 2/20 0.38
▸ SCN8A Q9UQD0 2/20 0.38
▸ SCN10A Q9Y5Y9 2/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ PPARD Q03181 2/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ NR1H4 Q96RI1 1/20 0.38
▸ BTK Q06187 1/20 0.38
▸ RIPK1 Q13546 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21407537 1.00 ROCK2 (0.42) ROCK2ROCK1SCN3AEPHX2PPARG
SCHEMBL30500793 0.88 ROCK2 (0.41) ROCK2ROCK1SCN3AEPHX2PPARG
SCHEMBL21407585 0.88 ROCK2 (0.41) ROCK2ROCK1SCN3AEPHX2PPARG
SCHEMBL21407611 0.87 SCN3A (0.44) ROCK2ROCK1SCN3AEPHX2ABL1
SCHEMBL30500794 0.87 SCN3A (0.44) ROCK2ROCK1SCN3AEPHX2ABL1
SCHEMBL21407606 0.86 PDE4A (0.39) ROCK2ROCK1EPHX2PPARGPPARD
SCHEMBL30500781 0.85 SCN3A (0.41) ROCK2ROCK1SCN3AEPHX2ABL1
SCHEMBL21407604 0.85 SCN3A (0.41) ROCK2ROCK1SCN3AEPHX2ABL1
SCHEMBL21407553 0.83 SCN3A (0.43) ROCK2ROCK1SCN3AEPHX2PPARG
SCHEMBL30500810 0.83 SCN3A (0.43) ROCK2ROCK1SCN3AEPHX2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702419-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702419-B2 Heterocyclic compound and use thereof GRIN2B, GRIN2A, GRIN2C ROCK2 3308/4885ROCK1 2914/4885SCN3A 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback